Potential for Glembatumumab Vedotin in TNBC

December 9, 2016
Linda T. Vahdat, MD, PhD

Linda T. Vahdat, MD, PhD, ‎Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).